Myo-Pericarditis and Congestive Heart Failure Secondary to Mesalamine Use Associated With Completely Reversible Cardiac Dysfunction

Luke Simon Olivera Yuhico, Pankaj Bharati, Stephen Knohl

Abstract


    Mesalamine is a 5-ASA derivative commonly used to treat ulcerative colitis and mild to moderate crohn’s disease. Rarely, it has been associated with myocarditis or pericarditis. Several hypotheses have been proposed but the exact mechanism of cardiac injury is still unclear. We present a case of combined pericarditis and myocarditis in a young man on mesalamine therapy, with subsequent deterioration of cardiac function, EKG changes and signs of congestive heart failure. After the appropriate treatment, beginning with discontinuation of mesalamine, he had complete recovery of cardiac function to normal. This case exemplifies the importance of quick physician recognition of the disease association and immediate discontinuation of the drug for more successful outcomes in conjunction with appropriate management.




doi:10.4021/jmc617w

Keywords


Mesalamine; Congestive heart failure; Myopericarditis; Drug effect

Full Text: HTML PDF
 

Browse  Journals  

     

Journal of clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 

 

 

 

Journal of Medical Cases, monthly, ISSN 1923-4155 (print), 1923-4163 (online), published by Elmer Press Inc.            
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.journalmc.org   editorial contact: editor@journalmc.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.